› 3sp6

X-ray diffraction
2.21Å resolution

Structural basis for iloprost as a dual PPARalpha/delta agonist

Released:
DOI: 10.2210/pdb3sp6/pdb
PDB entry 3sp6 coloured by chain, front view.
PDB entry 3sp6 coloured by chain, side view.
PDB entry 3sp6 coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Structural basis for iloprost as a dual peroxisome proliferator-activated receptor alpha/delta agonist.
Jin L, Lin S, Rong H, Zheng S, Jin S, Wang R, Li Y
J Biol Chem 286 31473-9 (2011)
PMID: 21775429

Function and Biology Details

Biochemical function:
Biological process:
Cellular component:
Sequence domains:

Structure analysis Details

Assembly composition:
hetero dimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-170554 (preferred)
Entry contents:
2 distinct polypeptide molecules
Macromolecules (2 distinct):
Peroxisome proliferator-activated receptor alpha Chain: A
Molecule details ›
Chain: A
Length: 285 amino acids
Theoretical weight: 32.34 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
UniProt:
  • Canonical: Q07869 (Residues: 196-468; Coverage: 58%)
Gene names: NR1C1, PPAR, PPARA
Sequence domains: Ligand-binding domain of nuclear hormone receptor
Structure domains: Retinoid X Receptor
Peroxisome proliferator-activated receptor gamma coactivator 1-beta Chain: B
Molecule details ›
Chain: B
Length: 11 amino acids
Theoretical weight: 1.21 KDa
Source organism: Homo sapiens
Expression system: Not provided
UniProt:
  • Canonical: Q86YN6 (Residues: 153-163; Coverage: 1%)
Gene names: PERC, PGC1, PGC1B, PPARGC1, PPARGC1B

Ligands and Environments

1 bound ligand:
Ligand IL2 1 x IL2
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: APS BEAMLINE 21-ID-F
Spacegroup: P21
Unit cell:
a: 44.837Å b: 60.973Å c: 54.16Å
α: 90° β: 108.99° γ: 90°
R-values:
R R work R free
0.179 0.176 0.239
Expression systems:
  • Escherichia coli
  • Not provided

Quick links

Citations

5 review citations

ROR nuclear receptors: structures, related diseases, and drug discovery.
Zhang et al. (2015)
4 more

14 mentions without citation

Development of Heterocyclic PPAR Ligands for Potential Therapeutic Applications.
Virendra et al. (2022)
13 more